Thiazides and related diuretics inhibit NaCl reabsorption in the distal tubule through an unknown mechanism. We report here that [3H~metolazone, a diuretic with a thiazide-like mechanism of action, labels a site in rat kidney membranes that has characteristics of the thiazide-sensitive ion transporter. [3HJMetolazone bound with high affinity (Kd = 4.27 nM) to a site with a density of 0.717 pmol/mg of protein in kidney membranes. Diuretics having a thiazide-like mechanism of action-i.e., inhibition of distal tubular NaCl reabsorption-include sulfonamides with a benzothiadiazine-dioxide ring (thiazides) as well as pharmacologically related sulfonamide diuretics differing in the heterocyclic ring, such as metolazone, quinethazone, indapamide, and chlorthalidone. To identify the molecular site of action of the thiazide diuretics, we have used radioligand binding methods to study the interaction of [3H]metolazone (7-chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-6-quinazolinesulfonamide) with rat kidney membranes in vitro. We report here that [3H]metolazone binds with high affinity to a site in the rat kidney that has characteristics consistent with its identity as the receptor for thiazide diuretics.
ion transporter. [3HJMetolazone bound with high affinity (Kd = 4.27 nM) to a site with a density of 0.717 pmol/mg of protein in kidney membranes. The binding site was localized to the renal cortex, with little or no binding in other kidney regions and 11 other tissues. The affinities of thiazide-type diuretics for this binding site were significantly correlated with their clinical potency. Halide anions (Cl1, Br-, and I-) specifically inhibited high-affinity binding of [3H] metolazone to this site. [3lHlMetolazone also bound with lower affinity (Kd = 289 nM) to sites present in kidney as well as in liver, testis, lung, brain, heart, and other tissues. Calcium antagonists and certain smooth muscle relaxants had K; values of 0.6 -10 gAM for these low-affinity sites, which were not inhibited by most of the thiazide diuretics tested. Properties of the high-affinity [3lHlmetolazone binding site are consistent with its identity as the receptor for thiazide-type diuretics.
Thiazide diuretics are among the most widely prescribed drugs in clinical practice and are mainstays in the therapy of hypertension and the management of edema. In the 30 years since the development of chlorothiazide (1, 2) , numerous other benzothiazide sulfonamides and pharmacologically related diuretics have been synthesized and have reached the clinic. Physiological studies have demonstrated that thiazides and closely related drugs act by inhibiting the reabsorption of NaCl in the distal tubule (3) . However, despite their widespread use and extensive studies, the molecular entities through which thiazides exert their effects and the exact cellular locations of these sites have not yet been identified.
Diuretics having a thiazide-like mechanism of action-i.e., inhibition of distal tubular NaCl reabsorption-include sulfonamides with a benzothiadiazine-dioxide ring (thiazides) as well as pharmacologically related sulfonamide diuretics differing in the heterocyclic ring, such as metolazone, quinethazone, indapamide, and chlorthalidone. To identify the molecular site of action of the thiazide diuretics, we have used radioligand binding methods to study the interaction of [3H]metolazone (7-chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-6-quinazolinesulfonamide) with rat kidney membranes in vitro. We report here that [3H]metolazone binds with high affinity to a site in the rat kidney that has characteristics consistent with its identity as the receptor for thiazide diuretics.
MATERIALS AND METHODS Materials. [3H]Metolazone was custom synthesized by
Amersham. The compound was prepared by reduction of the unsaturated precursor, 7-chloro-3,4-dihydro-2-methyl-4-oxo-3-o-tolyl-6-quinazolinesulfonamide, using sodium boro[PH]-hydride in aqueous ethanol (4) . The product was purified by TLC to >98% purity and had a specific activity of 11.3 Ci/mmol (1 Ci = 37 GBq). The purity of the [3H]metolazone was assessed by reverse-phase HPLC (5) and remained >98% throughout the course of the study.
Metolazone and its precursor were generously provided by Pennwalt (Rochester, NY). Diuretics were also donated by the following: bendroflumethiazide by Squibb, quinethazone by Lederle Laboratories (Pearl River, NY), polythiazide by Pfizer, benzthiazide by A. H. Robins (Richmond, VA), indapamide by Revlon Health Care (Tuckahoe, NY), chlorothiazide by Merck, trichlormethiazide by Schering, and methychlothiazide by Abbott. Ro 5-4864 was provided by Hoffmann-La Roche and PK 11195 was provided by Pharmuka (Gennevilliers, France). Other drugs were obtained from Sigma.
Tissue Preparation. Kidneys and other tissues were obtained from male Sprague-Dawley rats weighing 150-250 g. Tissues were homogenized with a Polytron (Brinkman) in ice-cold 50 mM Tris phosphate buffer (pH 7.4). Homogenates were centrifuged for 5 min at 120 x g and the supernatants were centrifuged for 20 min at 48,000 x g. The pellet was resuspended in fresh buffer and centrifuged again for 20 min at 48,000 x g. The resulting membrane pellet was resuspended in Tris phosphate buffer at a concentration of 0.8 mg of protein per ml for use in binding assays.
Binding Assays. Kidney membranes in 50 mM Tris phosphate buffer were incubated with [3H]metolazone and unlabeled compounds in a volume of 1 ml in an ice bath. Incubations were carried out for 4 hr, by which time steadystate conditions were attained. An incubation time of 2 hr was used for experiments measuring low-affinity binding, which reached steady state more rapidly than high-affinity binding. Membranes were collected by filtration through glass fiber filters (GF/B, Whatman) using a cell harvester (Brandel Instruments, Gaithersburg, MD) and washed with 12 ml of ice-cold Tris phosphate buffer. Filters were soaked for at least 1 hr prior to use with 0.3% polyethyleneimine, a procedure that increased the amount of specific binding retained. Radioactivity on the filters was extracted into BetaPhase scintillation cocktail (WestChem Products, San Diego, CA) and counted at an efficiency of 52% in a liquid scintillation counter. There was no specific binding of [3H]metolazone to the filters. Proteins were determined by the Bradford Coomassie blue method (Bio-Rad) with gamma globulin as the standard. Scatchard plots were analyzed with the LIGAND program of Munson and Rodbard (6) Bound, pmol/mg of protein Table 1 for the highaffinity binding site in rat kidney are positively correlated with the average daily dose of these drugs used clinically (Fig. 2) . The correlation coefficient (r = 0.7513) for the pA2 (-log K1) versus the logarithm of the average daily oral dose is significant at the P < 0.01 level.
The pharmacological profile of the low-affinity binding site in kidney membranes was determined by using [3H] (Table 3) . Within the kidney, high-affinity sites were almost entirely limited to the renal cortex. Much lower levels of specific binding were detected in the renal medulla and papilla and in the testis, adrenal gland, lung, spleen, liver, and pancreas, whereas in 5 other tissues no specific binding was present. The kidney also contained the greatest density of low-affinity binding sites, which were more concentrated in the renal cortex than in the medulla or papilla (Table 3) . Liver and testis contained half as great a density of low-affinity sites, whereas lung, brain, spleen, heart, and pancreas contained lower densities of these sites. Effect of Ions. Since thiazide diuretics are postulated to block a NaCl cotransporter in the distal nephron, we deter- . When these ions were tested at 100 mM for inhibition of low-affinity binding (data not shown), only choline chloride produced >50% inhibition.
DISCUSSION
The high-affinity binding site for [3H]metolazone described in this study has several properties expected of the receptor for thiazide diuretics. There exists a highly significant correlation (P < 0.01) between the affinity of several thiazides and thiazide-like diuretics for this binding site and their average daily clinical dose. These drugs include not only thiazides but also quinazolinones (metolazone itself and quinethazone), chlorthalidone, and indapamide, drugs that share a thiazide-like mechanism of action (i.e., inhibition of disial tubular NaCl reabsorption) but that do not contain the benzothiadiazide ring. This correlation is especially significant when one considers that the data are obtained in different species and that biological efficacy is affected by the varying pharmacokinetic profiles of these drugs. In addition, some drugs may have other sites of action that contribute to their biological effects. In particular, indapamide is reported to have smooth muscle relaxant properties (10) , which may produce a greater potency than would be obtained if interaction with thiazide receptors were its sole mechanism of action.
Much greater densities of high-affinity [3H]metolazone binding sites are present in the kidney than in other tissues. Low levels of hydroflumethiazide-displaceable binding measured in six other tissues (Table 3) were near the limits of detection, with very low ratios of specific to nonspecific binding. Micropuncture studies indicate that thiazidespecific effects upon chloride transport are produced in the distal tubule of the rat nephron (11) (12) (13) . The localization within the kidney of the high-affinity binding site, which is almost entirely limited to the cortex, is consistent with this site of action. A model epithelium that displays thiazideinhibitable NaCl transport (the urinary bladder of the winter flounder) has only recently been reported (14) , whereas ion transport in several other epithelial tissues is not affected by thiazides (15) . The present results suggest that the thiazide receptor may be less widely distributed than other ion transporters such as the loop diuretic-sensitive Na/K/Cl cotransporter, which occurs in numerous cell types outside of the kidney (16, 17) .
It is significant that chloride, iodide, and bromide at 100 mM greatly inhibited binding of [3H]metolazone to its highaffinity site, whereas sodium, potassium, and several monovalent and divalent anions were ineffective. This finding may indicate that thiazide diuretics and halide anions compete for a transport site or channel, although noncompetitive actions are not excluded by current data. Competition between diuretics and halide anions for the thiazide receptor is consistent with the physiological effects of thiazide diuretics, which not only produce chloruresis but also increase excretion of bromide and iodide (18) .
[3H]Metolazone bound to at least two lower-affinity sites.
One of these sites appeared to be a membrane-associated carbonic anhydrase, since acetazolamide blocked this binding site at concentrations below 1 ,uM. This acetazolamidesensitive portion of [3H]metolazone binding is of lower affinity than the two binding sites described here and is widely distributed, with especially high densities in salivary glands (unpublished data). Membrane-associated carbonic anhydrase isozymes have been identified but not yet completely characterized (19, 20) . It has been proposed that proximal tubular effects of metolazone and chlorothiazide are secondary to inhibition of carbonic anhydrase in this tubule segment (21) . With acetazolamide present to block carbonic anhydrase, [3H]metolazone bound to a low-affinity site or sites most prevalent in the kidney but also present in significant quantities in liver, testis, lung, brain, heart, spleen, and pancreas. Most thiazide diuretics did not inhibit this site at concentrations below 100 ,uM, the exceptions being two thiazides (methychlothiazide and polythiazide), which are both substituted in the 2-N position of the benzothiadiazine ring. Metolazone is also N-substituted in the analogous position of the quinazoline ring. It is of interest that a chemically diverse group of calcium channel blockers and smooth muscle relaxants inhibited low-affinity binding
with Ki values in a narrow range of 0.6-8 AuM. Ligands for the peripheral-type benzodiazepine receptor, which is localized in the distal nephron (22) and inhibited by metolazone at micromolar concentrations (23) , were relatively weak inhibitors of low-affinity binding. Biphasic dissociation of lowaffinity binding (unpublished data) and the shallow competition curves obtained with inhibitors, which yielded slope factors significantly less than unity, indicate that this component of binding may be heterogeneous or involve cooperative interactions (24) . Whether this component of metolazone binding may be significant for metolazone's reported effects in patients with limited renal function (25) remains to be determined.
In conclusion, [3H]metolazone binds to a high-affinity site that is limited to kidney, blocked by halide anions, and inhibited by diuretics with thiazide-like mechanisms of action. This radiolabeled probe should be useful in the molecular characterization of the receptor for thiazide-type diuretics.
